Equities

Strata Skin Sciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Strata Skin Sciences Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.345
  • Today's Change-0.045 / -11.54%
  • Shares traded1.56m
  • 1 Year change-88.31%
  • Beta0.4720
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.

  • Revenue in USD (TTM)30.98m
  • Net income in USD-11.04m
  • Incorporated1997
  • Employees106.00
  • Location
    Strata Skin Sciences Inc5 Walnut Grove Drive, Suite 140HORSHAM 19044United StatesUSA
  • Phone+1 (215) 619-3200
  • Fax+1 (215) 619-3209
  • Websitehttps://www.strataskinsciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sigyn Therapeutics Inc0.00-3.22m1.20m4.00---------2.01-2.010.00-3.690.00----0.00-1,144.23-590.29---------------3.44--------19.43------
Zynex Inc108.20m-73.96m1.22m1.00k------0.0112-2.43-2.433.49-1.341.262.207.64108,202.00-86.3110.48-203.5512.4271.9079.57-68.357.510.3174-12.223.19--4.3633.44-69.24-20.6129.29--
Nu-Med Plus Inc0.00-54.13k1.28m2.00---------0.0006-0.00060.00-0.00310.00----0.00-910.51-451.95---------------8.61--------45.55------
Escalon Medical Corp11.94m-200.38k1.44m39.00--1.40--0.1209-0.0436-0.04361.110.22592.573.677.31306,156.90-2.201.53-4.993.4845.3843.87-0.85520.70260.979-1.960.1335--0.53955.09115.88---42.12--
STRATA Skin Sciences Inc30.98m-11.04m2.03m106.00--1.38--0.0656-2.62-2.627.290.24940.87364.517.80292,264.20-31.13-14.64-52.77-21.5157.7659.75-35.64-21.510.746-4.020.921--0.61161.226.87---10.13--
Tivic Health Systems Inc482.00k-7.51m2.06m7.00--0.2423--4.27-9.87-9.870.59143.360.10022.0734.4368,857.14-156.00-118.40-178.18-148.80-58.095.50-1,557.26-610.995.86--0.00---33.6713.1831.40------
Agape ATP Corp1.48m-2.71m2.26m16.00--0.099--1.52-14.97-14.972.6122.830.104713.9960.1492,806.88-19.46-34.76-21.27-44.4452.6869.19-185.74-92.8616.18--0.0056---7.57---17.53------
Catheter Precision Inc730.00k-22.19m2.39m22.00--0.3473--3.27-37.38-37.380.93714.120.0281.646.3533,181.82-66.93-128.03-78.29-160.1292.60-242.70-2,393.84-15,268.880.4569-66.840.0449---4.98-19.8969.45---24.21--
Profusa Inc0.00-39.09m2.48m0.00---------278.73-278.730.00-61.050.00-------599.88-----------------14.56---------849.77------
INVO Fertility Inc6.94m-27.13m2.53m28.00------0.3644-602.89-644.6750.028.630.387419.5026.14247,996.40-149.96-63.14-299.48-98.9639.1760.46-387.11-276.300.1022-10.360.2530--116.2534.57-16.33--9.88--
Aethlon Medical Inc0.00-11.26m2.58m9.00--0.2597-----56.69-56.690.007.550.00----0.00-139.25-86.44-181.09-98.06-------3,662.04----0.00-------9.67------
Work Medical Technology Group Ltd9.85m-1.07m2.62m238.00--0.0071--0.2662-241.35-241.353,396.11214.42------41,381.18--1.52--4.5623.8122.30-12.192.521.50-7.760.23190.00-14.41-28.4569.28---39.54--
Fuse Medical Inc18.40m3.63m2.96m31.001.11--0.80140.16060.0360.0360.2307-0.00310.95930.70185.75593,671.9018.910.750448.451.3564.9554.9819.720.65520.3143-1.131.12---8.67-6.72295.1134.66----
Data as of Feb 13 2026. Currency figures normalised to Strata Skin Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

19.89%Per cent of shares held by top holders
HolderShares% Held
22NW LPas of 30 Sep 2025537.00k9.12%
Nantahala Capital Management LLCas of 30 Sep 2025403.92k6.86%
Renaissance Technologies LLCas of 30 Sep 2025101.53k1.72%
Abante Asesores Gesti�n SGIIC SAas of 31 Dec 202552.39k0.89%
Geode Capital Management LLCas of 30 Sep 202518.14k0.31%
The Vanguard Group, Inc.as of 31 Dec 202516.18k0.28%
Apollon Wealth Management LLCas of 31 Dec 202515.11k0.26%
G1 Execution Services LLCas of 30 Sep 202512.43k0.21%
Creative Planning LLCas of 30 Sep 202510.02k0.17%
BlackRock Fund Advisorsas of 30 Sep 20254.47k0.08%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.